Related Experiment Video

Updated: Jul 1, 2025

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

7.7K

Current status and future perspectives of FGF21 analogues in clinical trials

Zara Siu Wa Chui1, Qing Shen2, Aimin Xu3

  • 1State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, SAR, China; Department of Medicine, The University of Hong Kong, Hong Kong, SAR, China; School of Biomedical Sciences, The University of Hong Kong, Hong Kong, SAR, China.

Trends in Endocrinology and Metabolism: TEM
|February 29, 2024
PubMed

Insights

Fibroblast growth factor 21 (FGF21) analogues show promise for metabolic diseases, improving liver health and lipids. Combination therapies may enhance weight loss and glycemic control in obesity treatment.

Area of Science:

  • Pharmacology
  • Metabolic Diseases
  • Hepatology

Background:

  • Fibroblast growth factor 21 (FGF21) analogues are being developed for obesity-related metabolic comorbidities.
  • Current FGF21 therapies demonstrate mild and inconsistent effects on glycemic control and weight loss.

Purpose of the Study:

  • To review the therapeutic benefits of FGF21 analogues and antibody-based mimetics.
  • To explore the potential of combination therapies for enhanced efficacy.

Main Methods:

  • Review of recent clinical trial data for FGF21 analogues and mimetics.
  • Analysis of combination therapy studies involving FGF21 and other hormones like GLP-1.

Main Results:

  • FGF21 analogues show consistent improvements in dyslipidemia, hepatic steatosis, and metabolic dysfunction-associated steatohepatitis (MASH).
  • Reduction in liver fibrosis and injury biomarkers observed.
  • Emerging evidence suggests synergistic benefits when combined with hormones like GLP-1.

Conclusions:

  • FGF21 analogues offer therapeutic benefits for metabolic comorbidities, particularly liver health and lipid profiles.
  • Combination therapies hold potential for maximizing treatment efficacy in obesity and related conditions.
Keywords:
MASHcombination therapymetabolic syndromepeptide hormone

More Related Videos

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use10:33

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

795
In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

7.6K

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K